会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 10. 发明授权
    • Pyrazole derivatives, method for preparing same, and pharmaceutical
compositions containing said derivatives
    • 吡唑衍生物,其制备方法和含有所述衍生物的药物组合物
    • US6028084A
    • 2000-02-22
    • US068869
    • 1998-05-19
    • Francis BarthChristian CongySerge MartinezMurielle Rinaldi
    • Francis BarthChristian CongySerge MartinezMurielle Rinaldi
    • A61K31/00A61K31/415A61K31/445A61K31/4453A61P25/00A61P43/00C07D231/14C07D401/12
    • C07D231/14
    • Compounds of formula (I), wherein R.sub.1 is fluorine, hydroxy, (C.sub.1-5) alkoxy, (C.sub.1-5) alkylthio, hydroxy(C.sub.1-5)alkoxy, a -NR.sub.10 R.sub.11, group, cyano, (C.sub.1-5) alkyl-sulphonyl or (C.sub.1-5) alkylsulphinyl; R.sub.2 and R.sub.3 are each (C,.sub.4) alkyl or, taken together with the nitrogen atom to which they are attached, form a saturated or unsaturated 5- to 10-membered heterocyclic radical optionally substituted one or more times by (C.sub.1-3) alkyl or (C.sub.1-3) alkoxy; each of R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 is independently hydrogen, halogen or trifluoromethyl, and when R.sub.1 is fluorine, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and/or R.sub.9 may also be fluoromethyl; with the proviso that at least one of substituents R.sub.4 or R.sub.7. is other than hydrogen; each of R.sub.10 and R.sub.11 is independently hydrogen or (C.sub.1-5) alkyl, or R.sub.10 and R.sub.11, taken together with the nitrogen atom to which they are attached, form a heterocyclic radical selected from pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or piperazin-1-yl optionally substituted by (C.sub.1-4) alkyl; a method for preparing same, and pharmaceutical compositions containing said compounds, are disclosed. Said compounds have very high affinity for central cannabinoid receptors. ##STR1##
    • PCT No.PCT / FR96 / 01847 Sec。 371日期1998年5月19日 102(e)日期1998年5月19日PCT 1996年11月21日PCT PCT。 第WO97 / 19063号公报 日期:1997年5月29日,式(I)的化合物,其中R 1为氟,羟基,(C 1-5)烷氧基,(C 1-5)烷硫基,羟基(C 1-5)烷氧基,-NR 10 R 11基,氰基,(C 1 -5)烷基磺酰基或(C 1-5)烷基亚磺酰基; R 2和R 3各自为(C 1-4)烷基,或与它们所连接的氮原子一起形成任选被(C 1-3)取代一次或多次的饱和或不饱和的5至10元杂环基, 烷基或(C 1-3)烷氧基; R4,R5,R6,R7,R8和R9各自独立地是氢,卤素或三氟甲基,当R1是氟时,R4,R5,R6,R7,R8和/或R9也可以是氟甲基; 条件是至少一个取代基R4或R7。 不是氢; R 10和R 11各自独立地为氢或(C 1-5)烷基,或者R 10和R 11与它们所连接的氮原子一起形成选自吡咯烷-1-基,哌啶-1-基 ,任选被(C 1-4)烷基取代的吗啉-4-基或哌嗪-1-基; 公开了其制备方法和含有所述化合物的药物组合物。 所述化合物对中枢大麻素受体具有非常高的亲和力。